TY - JOUR T1 - The Impact of Timing of EGFR and IGF-1R Inhibition for Sensitizing Head and Neck Cancer to Radiation JF - Anticancer Research JO - Anticancer Res SP - 3029 LP - 3035 VL - 32 IS - 8 AU - FUMIHIKO MATSUMOTO AU - DAVID N. VALDECANAS AU - KATHRYN A. MASON AU - LUKA MILAS AU - K. KIAN ANG AU - UMA RAJU Y1 - 2012/08/01 UR - http://ar.iiarjournals.org/content/32/8/3029.abstract N2 - Background: Targeting the epidermal growth factor receptor (EGFR) improved radiotherapy outcome by 10-15% in head and neck tumors (HNSCC). We tested the therapeutic benefits of co-targeting EGFR and insulin-like growth factor-1 receptor (IGF-1R) to further enhance tumor response to radiation. Materials and Methods: Mice bearing FaDu tumor xenografts were treated with ganitumab (previously known as AMG479, an anti-IGF-1R antibody), panitumumab (an anti-EGFR antibody), or both in combination with fractionated doses of radiation. Tumor growth delay and tumor cure/recurrence served as end-points. Results: The best tumor growth delay was achieved when ganitumab and panitumumab were given concurrently with radiation. Tumor cure/recurrence studies showed that combining ganitumab, panitumumab and radiation resulted in significantly higher radiocurability rates than use of either of the agents given with radiation. Conclusion: These findings provide the rationale for clinical testing of the combination of ganitumab and panitumumab for the treatment of HNSCC. ER -